CN104411319A - Hawthorn and phytosterols and their effect on metabolic disorders - Google Patents
Hawthorn and phytosterols and their effect on metabolic disorders Download PDFInfo
- Publication number
- CN104411319A CN104411319A CN201380032880.4A CN201380032880A CN104411319A CN 104411319 A CN104411319 A CN 104411319A CN 201380032880 A CN201380032880 A CN 201380032880A CN 104411319 A CN104411319 A CN 104411319A
- Authority
- CN
- China
- Prior art keywords
- compositions
- body weight
- hfd
- phytosterol
- fructus crataegi
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
Abstract
The present invention generally relates to the field of health and wellness. In particular, the present invention addresses metabolic disorders and disorders associated therewith. For example, the present invention describes a composition comprising phytosterols and hawthorn for use in the treatment, alleviation or prevention of metabolic disorders.
Description
Generality of the present invention relates to healthy and happy field.Specifically, the present invention is directed to metabolic disease and relative disease.Such as, the invention describes the compositions comprising phytosterol and Fructus Crataegi, it is used for the treatment of, alleviate or prevent metabolic disease.
In the past few decades, the popular of obesity worldwide adds popular ratio.About have 1,000,000,000 people overweight or fat in the world, these situations add mortality rate, mobility and Financial cost.Occur fat when Energy intaking exceeds energy expenditure, unnecessary energy mainly with fat stores in fatty tissue.Reduce body weight and prevent body weight increase can realize by reducing Energy intaking or bioavailability, increase energy expenditure and/or reducing fat stores.Obesity represents the serious threat to health, because it is relevant with a series of chronic disease, comprises diabetes, atherosclerosis, degenerative disease, airway disorders and some cancer.
As everyone knows, Fructus Crataegi and phytosterol have health benefits, but this two constituents has it to limit.
Fructus Crataegi is rosaceous flowering plant.Its health benefits can see, for example the summary of Rigelsky and Sweet, Am J Health Syst Pharm March 1,200259:417-422. Fructus Crataegi have for cardiovascular disease from 1st century of Christian era long history so far.It has shown has good result to cholesterolemia reduction, and advises that it has beneficial effect to blood fat.
But in order to reach biological remarkable result, every day, edible haw juice often caused stomach discomfort due to its tart flavour.And on therapeutic dose, Fructus Crataegi can cause slight rash, headache, perspiration, dizziness, cardiopalmus, sleepiness, excitement and gastrointestinal symptom (Rigelsky and Sweet, Am J HealthSyst Pharm March 1,200259:417-422).
The known blood concentration that can be reduced T-CHOL and LDL-C by the cholesterol absorption of minimizing enteral of phytosterol.The reduction taking in 8% of about 2.4g phytosterol (or its saturated form stanol) and total cholesterol concentration in blood every day is relevant.Some indications are also had to show that phytosterol may have effect (Five phytosterols from Aloe Vera Gel as Anti-diabeticCompounds to diabetes; The people such as Tanaka, Biological and Pharmaceutical Bulletin rolls up 29 (2006), No.71418).But if used to measure significantly, phytosterol may have undesirable side effect.Such as, known they suppress α-and the absorption of beta-carotene.Beta-carotene is the important sources of vitamin A, and vitamin A is the necessary material of such as g and D.
When to avoid the low dosage of significant undesirable side effect or intestinal discomfort to use, Fructus Crataegi or plant sterol for metabolic disease as obesity does not have the effect of statistically significant.
But this kind of natural product of this area significant need, it can either be used safely and be free from side effects, and can also reduce the risk that metabolic disease occurs.
The present inventor meets this demand.
Therefore, the object of the invention is the state improving prior art, and a kind of natural composition is particularly provided, which overcome the problem of prior art and meet the demand.
Inventor surprisingly finds, the theme of independent claims achieves object of the present invention.The theme of dependent claims has further developed central idea of the present invention.
Specifically, inventor finds in Hamster model, when jointly using, Fructus Crataegi and phytosterol work synergistically, make the reduction of blood fat, body weight and Fat Accumulation generation statistically significant, keep phytosterol and Fructus Crataegi low dosage separately, described low dosage is enough to avoid undesirable side effect and discomfort simultaneously.
Therefore, the present invention partly relates to the compositions comprising phytosterol and Fructus Crataegi, and it is used for the treatment of, alleviate or prevent metabolic disease.
The invention still further relates to phytosterol and Fructus Crataegi for the preparation for the treatment of, alleviate or prevent the purposes in the compositions of metabolic disease.
The combination of Fructus Crataegi and phytosterol demonstrates the accumulation of prevention hyperlipidemia concentration very effective, especially on the feed during high fat diet.
For object of the present invention, if fat content is higher than recommended intake every day (RDI) at least 10%, at least 25%, at least 50%, at least 75% or at least 100%, then meals are considered " high fat ".
Therefore, it is possible to compositions of the present invention prevention, to alleviate or the metabolic disease for the treatment of can be relevant to hypertriglyceridemia.
Such as, described metabolic disease can be selected from overweight, fat, diabetes, hypertension, liver cirrhosis, metabolism syndrome and combination thereof.
" overweight " is defined as the BMI that adult has 25-30.
" Body Mass Index " or " BMI " refer to by kg body weight divided by the height by rice square ratio.
" obesity " is a kind of situation, and the natural energy deposit be wherein stored in the fatty tissue of animal (particularly people and other mammals) is increased to certain level, and now it is relevant to the mortality rate of some health status or increase." obesity " is defined as the BMI that adult has more than 30.
For generation further metabolic disease, particularly importantly high body weight, the fat mass especially raised.
Therefore, preventing or treat overweight and/or obesity is important application of the present invention.
Inventor can prove that compositions of the present invention can be used for preventing or reducing the accumulation of excessive perirenal fat.
Therefore, the present composition may be used for the increase of the ratio reducing or prevent perirenal fat and body weight.
On the feed during high fat diet, this is exceedingly useful.
Perirenal fat thickness is also the kidney resistance indices of chronic nephropathy, increase in type 2 diabetes mellitus patient and the individual index (people such as lamacchia, Nephrol.Dial.Transplant. (2011) 26 (3): 892-898) of hyperuricemia.Therefore, the present composition also can be used for treatment or prevents these diseases.
Inventor also finds, the present composition can be used for preventing or the accumulation that slims the abdomen well.
Therefore, the present composition may be used for the increase of the ratio reducing or prevent stomach fat and body weight.
Stomach fat can be around the interior fat of abdomen organ or the subcutaneous fat between skin and stomach wall.
The present composition has the effect for interior fat and subcutaneous fat.
Although well-known interior fat is main fat deposit, its to risk factor as insulin resistant is relevant, but nearest result also shows subcutaneous fat may take part in this kind of risk factor equally, especially (the people such as Goodpaster in man, Diabetes, October 1997, volume 46no.101579-1585).
The fat relation with generation noninsulindependent diabetes (NIDDM), between hypertension and cardiovascular disease is also the established simultaneously (people such as Smith, Metabolism, volume 50, No 4 (April), 2001:pp 425-435); Therefore, the present composition also can be used to treatment or prevents these diseases.
Equally, for the individuality of not suffering from metabolic disease, the present composition also may be useful.They such as can be used for helping body weight control.
Body weight control can be conducive to maintaining or improve the individual satisfaction to its outward appearance and happiness.
Body weight control also can be considered the prevention of risk measure reducing and suffer from metabolic disease.
Therefore, the present composition can be used for helping body weight control.
In treatment use, compositions is to be enough to cure or stop the amount of the symptom of disease and/or its complication to use at least in part.The amount being enough to realize this point is defined as " treatment effective dose ".The amount that effectively can realize this object depends on many factors well known by persons skilled in the art, the seriousness of such as disease and the body weight of patient and general state.
In prophylactic applications, compositions of the present invention is administered to patient that is that easily suffer from specified disease or that have disease risks, and its amount of application is enough to reduce the risk that disease occurs at least in part.Described amount is defined as " prevention effective dose ".Equally, accurate amount depends on the factor of multiple patient-specific, the health status of such as patient and body weight.
The present composition is effective according to dose-effect curve.They can to treat effective dose or to prevent effective dose to use.Technical staff can determine these dosage aptly.
But the present composition generally can be used with the amount being equivalent to per kilogram of body weight every day at least 0.5g, 1g or 3g Fructus Crataegi and at least 2.5mg, 15mg or 40mg phytosterol.
Such as, the present composition can comprise per kilogram of body weight every day at least 0.5g Fructus Crataegi and at least 2.5mg phytosterol.
Or the present composition can comprise per kilogram of body weight every day at least 1g Fructus Crataegi and at least 15mg phytosterol.
Or the present composition can comprise per kilogram of body weight every day at least 3g Fructus Crataegi and at least 40mg phytosterol.
In order to avoid undesirable side effect, such as abnormal flavour or suppression vitamin A absorption, described dosage should remain on rational low-level.
Such as, the dosage of Fructus Crataegi can be no more than 2.5g/ kg body weight/sky, and the dosage of phytosterol can be no more than 40mg/ kg body weight/sky.
Fructus Crataegi can provide with any form being applicable to being administered to human or animal.Such as, Fructus Crataegi can provide with fresh fruit, dry fruit reality, Folium Crataegi or the form with its extract.
The typical phytosterol that can be used for the object of the invention can be selected from plant sterol, stanol or its combination.
Example comprises cupreol, campesterol and/or stigmasterol.
Phytosterol can provide with chemically pure compound.Therefore, they from plant origin purification or can pass through chemosynthesis.This provide point-device administration.
Phytosterol from natural origin or its extract also can be preferably provided.Therefore, phytosterol can be meals phytosterol.They can provide with vegetable oil, nut, cereal product, veterinary antibiotics, berry or the form with its extract.
Compositions can be suitable for any compositions that human or animal eats.
Therefore, compositions can be selected from food, beverage, functional food, nutraceutical, food additive, nutritional formulas and pet food.
Because metabolic disease not only betides people, also occur in animal, compositions of the present invention can be administered to human or animal, and such as companion animals is as cat or Canis familiaris L..
Advantageously, compositions of the present invention can be edible in the short time in the short time before edible high fat diet, simultaneously or after a while.
So compositions can be used in the time frame of 1 hour after 1 hour to high fat diet before high fat diet.
It will be appreciated by those skilled in the art that when not deviating from the disclosed scope of the invention, they freely can combine all features of the present invention as herein described.Especially, the described feature for purposes of the present invention can be applied in compositions of the present invention, and vice versa.
Other advantages of the present invention and feature can be known and find out from embodiment hereafter and accompanying drawing.
Fig. 1 shows with the combined therapy of the Fructus Crataegi of same dose and plant sterol significantly and cause the steady decrease of the blood triglyceride of HFD hamster synergistically.Carry out analytical data by one factor analysis of variance, carry out Tukey multiple comparative test and unpaired Students t test subsequently.Meansigma methods ± SEM, n=8-12, * P<0.05, relative to contrast;
p<0.05, relative to HFD-placebo.
Fig. 2 shows with the combined therapy of the Fructus Crataegi of same dose and plant sterol significantly and cause the steady decrease that the body weight of HFD hamster increases synergistically.Carry out analytical data by one factor analysis of variance, carry out Tukey multiple comparative test and unpaired Students t test subsequently.Meansigma methods ± SEM, n=8-12, * P<0.05, relative to contrast;
p<0.05, relative to HFD-placebo.
Fig. 3 shows with the combined therapy of the Fructus Crataegi of same dose and plant sterol significantly and cause the steady decrease that the perirenal fat of HFD hamster increases synergistically.Carry out analytical data by one factor analysis of variance, carry out Tukey multiple comparative test and unpaired Students t test subsequently.Meansigma methods ± SEM, n=8-12, * P<0.05, relative to contrast;
p<0.05, relative to HFD-placebo.
Fig. 4 shows with the combined therapy of the Fructus Crataegi of same dose and plant sterol significantly and cause the steady decrease that the stomach fat of HFD hamster increases synergistically.Carry out analytical data by one factor analysis of variance, carry out Tukey multiple comparative test and unpaired Students t test subsequently.Meansigma methods ± SEM, n=8-12, * P<0.05, relative to contrast;
p<0.05, relative to HFD-placebo.
Embodiment
Syrian golden hamster is weighed about 120-130g, purchased from Beijing Vital River LaboratoryAnimal company limited.Animal is housed in (22-24 DEG C and 12h illumination-12h dark) in controllable environment, freely takes food tap water and food.
After the adaptation of a week, hamster is assigned randomly to different experimental grouies.By carrying out induced hyperlipidemia to detoxification High cholesterol diet, and measure the plasma TC, TG and the HDL-C level that raise.Described diet becomes to assign to prepare (g/kg) by mixing is following:
Component powders is mixed with the ratio of often liter of solution 200g diet with gelatin solution (20g/L).Once gelatin solidifies, diet is cut into the little fourth of about 10g, stored frozen at-80 DEG C until use.
Experimental group is as follows:
1) contrast: normal diet group (n=12)
2) HFD: high fat diet group (n=12)
3) HFD-H: the Fructus Crataegi slurry (fresh fruit 5g/kg/ days, n=12) in high fat diet
4) HFD-PS: the plant sterol esters (plant sterol esters 0.15g/kg/ days, n=12) in high fat diet
5) HFD-PS/H: the Fructus Crataegi slurry in high fat diet and plant sterol esters (n=12)
1. plant sterol (PS) and Fructus Crataegi (H) synergism that blood triglyceride (TG) is reduced
Background: medically, hypertriglyceridemia represents the high level of triglyceride in blood, and triglyceride is fats molecule the abundantest in most organism.It is relevant to atherosclerosis, even if it is also like this for there is not hypercholesterolemia (elevated cholesterol).Its also can cause when excessive concentrations pancreatitis (that is, when triglyceride concentration higher than, often far above 1000mg/dl or 12mmol/l time).
Blood triglyceride: after the process of 6 weeks, high fat diet significantly increases the blood triglyceride (table 1, HFD-placebo is relative to contrast) of 126mg/dL.Independent plant sterol show blood triglyceride in HFD hamster steady decrease (Fig. 1, HFD-PS relative to contrast, P>0.05; HFD-PS relative to HFD-placebo,
p<0.05).Although Fructus Crataegi does not show independent reducing effect, the effect which increasing plant sterol reduction blood triglyceride reaches 8.8mg/dL.
Table 1. Fructus Crataegi (H) and plant sterol (PS) blood triglyceride in high fat diet (HFD) hamster reduces effect.
2. Fructus Crataegi (H) and plant sterol (PS) are to the synergy of the reduction of body weight and fatty tissue
The cancer of background: excessive body weight is relevant to various diseases, particularly cardiovascular disease, type 2 diabetes mellitus, obstructive sleep apnea, some type and osteoarthritis.Therefore, fat reduction life expectancy is found.
2.1 body weight: after process in 8 weeks, high fat diet is significantly put on weight 45.6g (table 2, HFD-placebo relative to contrast).Compared with HFD-placebo (Fig. 2, HFD-H, HFD-PS relative to contrast, * P<0.05; HFD-H, HFD-PS relative to HFD-placebo, P>0.05), with plant sterol or Fructus Crataegi process, body weight is not significantly changed.Although this two constituents itself does not show significant protective effect separately, Fructus Crataegi and the plant sterol combined therapy under same dosage significantly reduce compared with HFD-placebo body weight (Fig. 3 .1, HFD-PS/H relative to HFD-placebo,
p<0.05).In addition, combined therapy shows the collaborative reduction effect (table 2) to body weight for treating separately.
Table 2. Fructus Crataegi (H) and the Body weight reducing effect of plant sterol (PS) in high fat diet (HFD) hamster
2.2 perirenal fats: after process in 8 weeks, high fat diet significantly increases the ratio (table 3, HFD-placebo is relative to contrast) of perirenal fat and body weight.Compared with HFD-placebo (Fig. 3, HFD-H, HFD-PS relative to contrast, * P<0.05; HFD-H, HFD-PS relative to HFD-placebo, P>0.05), with plant sterol or Fructus Crataegi process, body weight is not significantly changed.Although this two constituents itself does not show significant protective effect separately; but Fructus Crataegi and the plant sterol combined therapy under same dosage significantly reduces ratio (Fig. 3 of perirenal fat and body weight compared with HFD-placebo; HFD-PS/H is relative to HFD-placebo
p<0.05).
Table 3. Fructus Crataegi (H) and plant sterol (PS) perirenal fat in high fat diet (HFD) hamster reduces effect
2.3 stomach fats: after process in 8 weeks, high fat diet significantly increases the ratio (table 4, HFD-placebo is relative to contrast) of stomach fat and stomach fat and body weight.Compared with HFD-placebo (Fig. 4, HFD-H, HFD-PS relative to contrast, * P<0.05; HFD-H, HFD-PS relative to HFD-placebo, P>0.05), with plant sterol or Fructus Crataegi process, body weight is not significantly changed.Although this two constituents itself does not show significant protective effect separately; but Fructus Crataegi and the plant sterol combined therapy under same dosage significantly reduces ratio (Fig. 4 of stomach fat and body weight compared with HFD-placebo; HFD-PS/H is relative to HFD-placebo
p<0.05).
Table 4. Fructus Crataegi (H) and plant sterol (PS) stomach fat in high fat diet (HFD) hamster reduces effect
Claims (14)
1. comprise the compositions of phytosterol and Fructus Crataegi, it is used for the treatment of, alleviate or prevent metabolic disease.
2. compositions according to claim 1, wherein said metabolic disease is relevant to hypertriglyceridemia.
3., according to the compositions of any one of the claims, wherein said metabolic disease is selected from overweight, fat, diabetes, hypertension, liver cirrhosis, metabolism syndrome and its combination.
4., according to the compositions of any one of the claims, it is for reducing or prevent the increase of ratio of perirenal fat and body weight.
5., according to the compositions of any one of the claims, it is for reducing or prevent the increase of ratio of stomach fat and body weight.
6., according to the compositions of any one of the claims, it is for helping body weight control.
7., according to the compositions of any one of the claims, wherein said compositions is used with the daily dose being equivalent to per kilogram of body weight every day at least 0.5g, 1g or 3g Fructus Crataegi and at least 2.5mg, 15mg or 40mg phytosterol.
8., according to the compositions of any one of the claims, wherein Fructus Crataegi provides with fresh fruit, dry fruit reality, Folium Crataegi or the form with its extract.
9., according to the compositions of any one of the claims, wherein phytosterol is selected from plant sterol and stanol; Such as cupreol, campesterol and stigmasterol.
10. according to the compositions of any one of the claims, wherein phytosterol is meals plant sterols, and provides with vegetable oil, nut, cereal product, veterinary antibiotics and berry or with the form of its extract.
11. according to the compositions of any one of the claims, and wherein said compositions is selected from food, beverage, functional food, nutraceutical, food additive, nutritional formulas and pet food.
12. according to the compositions of any one of the claims, and wherein said compositions is administered to adult or old man.
13. according to the compositions of any one of the claims, and wherein said compositions is administered to human or animal, such as companion animals, such as cat or Canis familiaris L..
14. according to the compositions of any one of the claims, and wherein said compositions was used in the time frame of 1 hour after 1 hour to high fat diet before high fat diet.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201380032880.4A CN104411319A (en) | 2012-07-23 | 2013-07-22 | Hawthorn and phytosterols and their effect on metabolic disorders |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2012/079037 | 2012-07-23 | ||
| PCT/CN2012/079037 WO2014015462A1 (en) | 2012-07-23 | 2012-07-23 | Hawthorn and phytosterols and their effect on metabolic disorders |
| PCT/EP2013/065449 WO2014016265A1 (en) | 2012-07-23 | 2013-07-22 | Hawthorn and phytosterols and their effect on metabolic disorders |
| CN201380032880.4A CN104411319A (en) | 2012-07-23 | 2013-07-22 | Hawthorn and phytosterols and their effect on metabolic disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104411319A true CN104411319A (en) | 2015-03-11 |
Family
ID=52648737
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201380032880.4A Pending CN104411319A (en) | 2012-07-23 | 2013-07-22 | Hawthorn and phytosterols and their effect on metabolic disorders |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104411319A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109513006A (en) * | 2018-12-18 | 2019-03-26 | 江苏大学附属医院 | It is a kind of to treat metabolic syndrome morbidity drug and its measuring method |
| CN109596844A (en) * | 2018-12-18 | 2019-04-09 | 江苏大学附属医院 | It is a kind of to detect the drug and application that metabolic syndrome is fallen ill |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002043506A2 (en) * | 2000-12-01 | 2002-06-06 | N.V. Nutricia | Cholesterol lowering supplement |
| WO2007039040A1 (en) * | 2005-09-30 | 2007-04-12 | Unilever N.V. | Food composition |
| CN101642247A (en) * | 2009-06-26 | 2010-02-10 | 安徽燕之坊食品有限公司 | Instant food capable of decreasing blood lipid and blood pressure and processing method thereof |
| CN102488198A (en) * | 2011-11-18 | 2012-06-13 | 天津天狮生物发展有限公司 | Antioxidant health food preparation for protecting cardiovascular system and its preparation method |
-
2013
- 2013-07-22 CN CN201380032880.4A patent/CN104411319A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002043506A2 (en) * | 2000-12-01 | 2002-06-06 | N.V. Nutricia | Cholesterol lowering supplement |
| WO2007039040A1 (en) * | 2005-09-30 | 2007-04-12 | Unilever N.V. | Food composition |
| CN101642247A (en) * | 2009-06-26 | 2010-02-10 | 安徽燕之坊食品有限公司 | Instant food capable of decreasing blood lipid and blood pressure and processing method thereof |
| CN102488198A (en) * | 2011-11-18 | 2012-06-13 | 天津天狮生物发展有限公司 | Antioxidant health food preparation for protecting cardiovascular system and its preparation method |
Non-Patent Citations (1)
| Title |
|---|
| YUGUANG LIN ET AL: "Triterpenic Acids Present in Hawthorn Lower Plasma Cholesterol by Inhibiting Intestinal ACAT Activity in Hamsters", 《EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109513006A (en) * | 2018-12-18 | 2019-03-26 | 江苏大学附属医院 | It is a kind of to treat metabolic syndrome morbidity drug and its measuring method |
| CN109596844A (en) * | 2018-12-18 | 2019-04-09 | 江苏大学附属医院 | It is a kind of to detect the drug and application that metabolic syndrome is fallen ill |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105126067B (en) | A kind of composition of anti-trioxypurine and application thereof | |
| WO2014131344A1 (en) | Beverage | |
| CN105727081A (en) | Healthcare product composition for treating gout | |
| CN104223107A (en) | Healthcare product with liver-protecting, hangover-alleviating and toxin-eliminating functions | |
| CN107467497A (en) | A kind of five cereals food therapeutic composition with anti-adiposity health care function and preparation method thereof | |
| CN102920743A (en) | Application of spirulina in preparation of anti-hyperuricemia and anti-uarthritis medicine or health-care food | |
| CN102599289A (en) | Pomegranate health-care tea | |
| CN105851360A (en) | Preparation method for health food capable of substantially improving blood sugar and blood fat and rapidly supplementing trace elements essential for human body | |
| CN103519267A (en) | Honey vinegar health drink and preparation method thereof | |
| CA2511195A1 (en) | Ayurvedic herbal soft drink | |
| CN104379214A (en) | Kudzu and phytosterols for use in the treatment of metabolic disorders | |
| CN104411319A (en) | Hawthorn and phytosterols and their effect on metabolic disorders | |
| CN102526346A (en) | Health-care pharmaceutical formulation with immunity-enhancing and senility-delaying functions | |
| CN106360735A (en) | Food composition assisting in reducing blood sugar and blood fat | |
| CN106728108A (en) | A kind of hypertension and hyperlipemia Chinese medicine composition containing gynostemma pentaphylla | |
| CN103535625A (en) | Food for regulating and controlling blood glucose and preparation method thereof | |
| WO2014016265A1 (en) | Hawthorn and phytosterols and their effect on metabolic disorders | |
| CN102366094A (en) | Fat-reducing and hypolipemic health food | |
| JP2010030950A (en) | Prophylactic and therapeutic agent for metabolic syndrome and functional food | |
| WO2013117733A1 (en) | Kudzu and plant sterols and their effect on cardiovascular diseases | |
| JP2004329047A (en) | Dietary supplement | |
| CN103431396A (en) | Natural plant buccal tablet for and preparation technique thereof | |
| WO2014016266A1 (en) | Kudzu and phytosterols for use in the treatment of metabolic disorders | |
| KR100532556B1 (en) | Composition for treating obesity and constipation containing extract of pine needle, green tea and black tea as an active ingredient | |
| WO2013117731A1 (en) | Hawthorn and kudzu and their effect on cardiovascular diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| EXSB | Decision made by sipo to initiate substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150311 |
|
| RJ01 | Rejection of invention patent application after publication |